S. A. L. MONTALVAO, A. C. TUCUNDUVA, L. H. SIQUEIRA, A. L. A. SAMBO, S. S. MEDINA and M. C. OZELO
The development of inhibitory antibodies against factor VIII (FVIII), also called inhibitors, can occur in approximately 25 a 30% of haemophilia A patients after repeated infusions of FVIII protein [1–3]. The inhibitor presence is a major complication, leading to a significant increase in the morbidity, and resulting in a negative impact in the quality of life of the…
